Cerus Corporation (NASDAQ:CERS) Short Interest Up 38.9% in August

Key Points

• Cerus Corporation experienced a significant increase in short interest, rising by 38.9% in August, totaling 9,740,000 shares as of August 15th.
• The company reported a loss of ($0.03) earnings per share for the last quarter, missing analysts' estimates, but exceeded revenue expectations with $60.10 million in revenue.
• Institutional investors now own approximately 78.37% of Cerus’ shares, indicating strong institutional interest in the biotechnology firm.

Cerus Corporation (NASDAQ:CERS - Get Free Report) was the target of a large increase in short interest in the month of August. As of August 15th, there was short interest totaling 9,740,000 shares, anincreaseof38.9% from the July 31st total of 7,010,000 shares. Based on an average daily volume of 1,240,000 shares, the days-to-cover ratio is currently 7.9 days. Based on an average daily volume of 1,240,000 shares, the days-to-cover ratio is currently 7.9 days.

Institutional Trading of Cerus

Several large investors have recently bought and sold shares of the company. Wasatch Advisors LP grew its position in shares of Cerus by 2.6% during the second quarter. Wasatch Advisors LP now owns 8,533,758 shares of the biotechnology company's stock worth $12,033,000 after buying an additional 213,917 shares in the last quarter. Millennium Management LLC boosted its holdings in shares of Cerus by 12.0% in the 1st quarter. Millennium Management LLC now owns 3,222,327 shares of the biotechnology company's stock valued at $4,479,000 after buying an additional 344,395 shares during the period. Acadian Asset Management LLC boosted its holdings in shares of Cerus by 38.6% in the 2nd quarter. Acadian Asset Management LLC now owns 2,632,304 shares of the biotechnology company's stock valued at $3,710,000 after buying an additional 733,683 shares during the period. Ieq Capital LLC boosted its holdings in shares of Cerus by 4.2% during the second quarter. Ieq Capital LLC now owns 2,418,263 shares of the biotechnology company's stock valued at $3,410,000 after acquiring an additional 97,467 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Cerus by 6.5% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,774,137 shares of the biotechnology company's stock valued at $2,466,000 after acquiring an additional 107,771 shares during the period. Institutional investors and hedge funds own 78.37% of the company's stock.

Cerus Stock Performance

Shares of CERS opened at $1.33 on Monday. The stock has a market cap of $254.96 million, a price-to-earnings ratio of -13.30 and a beta of 1.63. The company has a debt-to-equity ratio of 1.01, a current ratio of 2.00 and a quick ratio of 1.35. The firm has a 50 day simple moving average of $1.34 and a 200-day simple moving average of $1.37. Cerus has a 1-year low of $1.12 and a 1-year high of $2.24.

Cerus (NASDAQ:CERS - Get Free Report) last released its earnings results on Tuesday, August 5th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.01). The firm had revenue of $60.10 million during the quarter, compared to analysts' expectations of $51.80 million. Cerus had a negative net margin of 9.81% and a negative return on equity of 33.77%. Cerus has set its FY 2025 guidance at EPS. Equities analysts forecast that Cerus will post -0.08 EPS for the current fiscal year.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.